secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sarepta Therapeutics, Inc. (SRPT)
CIK:        0000873303
Form:       8-K
Filed at:   2026-02-25T23:59:59+00:00
Accession:  0001193125-26-071566
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sarepta reports Q4 2025 net loss of $412.2M; full-year revenue up 16% to $2.2B
------------------------------------------------------------------------------

- Full-year 2025 net product revenue $1,864.3M (PMO $965.6M, ELEVIDYS $898.7M); Q4 net product revenue $369.6M.
- GAAP net loss Q4 $412.2M ($3.93/share) vs Q4 2024 net income $159.0M; full-year GAAP net loss $713.4M.
- Ended 2025 with ~$1.0B cash; refinanced $291.4M of 2027 notes to 2030 notes, removing near-term debt.
- Japan launch of ELEVIDYS by Chugai in Feb 2026; eligible for $40M milestone. Positive 3-year EMBARK results.
- Approval to begin Phase 1 trial of SRP-1005 (siRNA) for Huntington’s disease; Phase 1/2 SRP-1003 for DM1 advancing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/873303/000119312526071566/0001193125-26-071566-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/873303/000119312526071566/srpt-20260225.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-071566

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer